Tethering telomeres to the inner nuclear membrane (INM) allows homologous chromosome pairing during meiosis. The meiosisspecific protein TERB1 binds the telomeric protein TRF1 to establish telomere-INM connectivity and is essential for mouse fertility. Here we solve the structure of the human TRF1-TERB1 interface to reveal the structural basis for telomere-INM linkage. Disruption of this interface abrogates binding and compromises telomere-INM attachment in mice. An embedded CDK-phosphorylation site within the TRF1-binding region of TERB1 provides a mechanism for cap exchange, a late-pachytene phenomenon involving the dissociation of the TRF1-TERB1 complex. Indeed, further strengthening this interaction interferes with cap exchange. Finally, our biochemical analysis implicates distinct complexes for telomere-INM tethering and chromosome-end protection during meiosis. Our studies unravel the structure, stoichiometry, and physiological implications underlying telomere-INM tethering, thereby providing unprecedented insights into the unique function of telomeres in meiosis.
a r t i c l e s Telomeres are nucleoprotein complexes found at chromosome ends that play a critical role in the maintenance of genome stability. Mammalian telomeres are composed of tandem DNA repeats of the GGTTAG/CCAATC sequence ending with a 3′ guanosine-rich single-strand overhang 1, 2 . Mammalian telomeric DNA is coated with many copies of shelterin, a six-protein complex consisting of TRF1, TRF2, TPP1, POT1, TIN2 and Rap1 (ref. 3) . TRF1 and TRF2 are the two double-stranded telomeric-DNA-binding proteins within shelterin [4] [5] [6] . By binding specifically and with high affinity to telomeric DNA, shelterin performs multiple critical functions. First, shelterin protects telomeric DNA from being inappropriately recognized as a double-stranded break 3 . Second, shelterin is critical for the recruitment of the reverse transcriptase telomerase, which replicates the extreme ends of chromosomes 7 .
In cells undergoing meiosis to produce haploid gametes for sexual reproduction 8, 9 , shelterin must fulfill a third critical function. Specifically, telomeres attach to the INM in meiotic prophase I. The LINC complex [10] [11] [12] , consisting of SUN-domain and KASH-domain proteins, is important for linking chromosomes to the cytoskeletal motors, which enable chromosomal movement along the membrane [13] [14] [15] [16] [17] [18] . This telomere-INM connection is thought to be important in enabling the proper pairing of homologous chromosomes and subsequent recombination. The recombination events are critical for producing genetic variation and important for ensuring proper segregation of homologous chromosomes during the first meiotic metaphase. While Bqt1 and Bqt2 proteins are involved in telomere-INM tethering in Schizosaccharomyces pombe, the Ndj1 protein performs a similar function in Saccharomyces cerevisiae 19, 20 . In contrast, the corresponding mammalian proteins cannot be detected using sequencebased homology searches.
Nevertheless, the recent identification of genes that are specifically expressed in mouse tissues undergoing meiosis by Shibuya et al. 21, 22 has led to the discovery of genes responsible for INM tethering of telomeres in mammals. The protein encoded by one of these genes, the telomere repeats-binding bouquet-formation protein (TERB1) 21 , is conserved amongst vertebrates and essential for fertility in mice. TERB1 is expressed only during meiotic prophase I, when it colocalizes with telomeres. Terb1 −/− mice showed impaired meiosis due to loss of synapsis, lack of homologous chromosome pairing, and reduced chromosome movement during meiotic prophase I. These studies showed the importance of TERB1 for connecting telomeres to the cellular machinery via the nuclear membrane 21 . TERB1 was shown to directly interact with the shelterin component TRF1. The C terminus of TERB1 (TRF1-binding domain or TERB1 TRFB ; amino acids (aa) 523-656 for human TERB1 (hTERB1)) and the dimerization domain of TRF1 (TRF-homology domain or TRF1 TRFH ; aa 62-265 for human TRF1 (hTRF1)) are necessary and sufficient for this interaction 21 . TERB2 and MAJIN are two other meiotic telomere-INM proteins that were subsequently discovered 22, 23 . TERB2 forms a stable complex with TERB1 and links it to MAJIN, which is anchored to the INM (Fig. 1a) . Tethering of telomeres to the INM is followed by an intriguing phenomenon coined telomere-cap exchange that occurs late in pachytene. During cap exchange, shelterin dissociates from its meiotic binding partners, resulting in a central TERB1-TERB2-MAJIN focus at telomeres surrounded by a more diffuse shelterin signal 22 . Despite the recent mapping of the interactions that connect telomeres to the INM (Fig. 1a) , the structural basis for telomere-INM tethering remains completely unknown. How TRF1-TERB1 binding is switched on for initial INM attachment in early prophase I and then off during cap exchange later in prophase I is also poorly understood. Here we use a combination of X-ray crystallography, quantitative biochemistry, mouse meiosis models, and high-resolution microscopy of telomere-INM complexes to answer these critical questions in mammalian meiosis.
RESULTS

TERB1 uses a variation of the strategy employed by TIN2 to bind TRF1
We noted that the CDK consensus motif ((S/T)PX(K/R)) in the TERB1 TRFB domain 21 , 648 TPRR 651 , overlaps with a sequence that resembles the 'FXLXP' TRFH-binding motif (TBM) that TIN2 ( 258 FNLAP 262 of TIN2) uses to bind TRF1 (ref. 24) ( Fig. 1a) . 645 ILLTP 649 of TERB1 satisfies the FXLXP consensus sequence, barring the presence of a phenylalanine→isoleucine substitution. The characteristic 'arginine tail' C terminal to the FXLXP motif in TIN2 is also present in TERB1 TBM (TERB1 (aa) 643-656; Fig. 1a ). Also knowing that the TERB1 TRFB domain is sufficient to bind TRF1 (refs. 21, 22) , we hypothesized that TERB1 binds TRF1 using a TBM. Indeed, GST-hTERB1 TBM efficiently pulls down TRF1 TRFH (Fig. 1b) .
To determine the structural basis for the TRF1-TERB1 interaction, we crystallized and solved the structure of the hTRF1 TRFH -hTERB1 TBM complex to 2.1 Å ( Table 1) . The structure revealed two TERB1 TBM peptides bound to the two monomers of a TRF1 TRFH homodimer ( Fig. 1c and Supplementary Fig. 1a,b ). Next, we compared the interactions of TERB1 and TIN2 with TRF1 side by side, based on the new TRF1 TRFH -TERB1 TBM structure and the previously reported TRF1 TRFH -TIN2 TBM structure 24 . TIN2 F258 binds a pocket of TRF1 lined by hydrophobic residues (Fig. 1d , center and right). In sharp contrast, the equivalent TERB1 I645 residue is mostly excluded from this pocket ( Fig. 1d,h) . Interestingly, TERB1 L646, which occupies a variable position in the (F/I)XLXP motif (underlined), partially occupies this hydrophobic pocket of TRF1 (Fig. 1d) . The conserved LXP motif of TERB1 and TIN2 adopts very similar conformations in both structures ( Fig. 1e,h) . Finally, although the second arginine of the TRF1-binding motif in TIN2 ( 265 RRR 267 ) makes several important interactions with TRF1, it is the third arginine in this motif of TERB1 ( 650 RRR 652 ) that occupies a similar spatial position and participates in the equivalent interactions ( Fig. 1f,h) .
Our structure reveals the mechanism by which CDK phosphorylation of TERB1 T648 blocks the binding of TERB1 to TRF1, thereby releasing telomeres from their tether at the INM in late pachytene 21 . The proximity of the side chains of TERB1 T648 and TRF1 E106 (3.0 Å; Fig. 1g ) suggests that phosphorylation of TERB1 T648 (PO 4 -T648) would result in electrostatic repulsion between two negatively charged residues, thus leading to the disruption of the binding interface. Overall, our structural analysis of the TRF1-TERB1 interaction reveals an interface similar to, but less intimate than, the interface formed between TIN2 and TRF1.
Biochemical and biophysical validation of the TERB1-TRF1 interface
We performed GST-pulldown experiments using GST-TRF1 TRFH as bait and His-Smt3-tagged TERB1 TBM wild-type (WT) or mutant constructs as prey. Whereas GST-TRF1 TRFH pulled down WT TERB1 TBM , the I645E, L647E, T648E (phosphomimetic mutation), P649E, and R652E mutations of TERB1 645 ILLTPRRR 652 resulted in a complete loss of pulldown ( Supplementary Fig. 2a ). We asked how replacing TERB1 I645 with a phenylalanine residue to create an FXLXP ( 645 FLLTP 649 ) motif would affect TRF1 binding. TERB1 TBM I645F was pulled down by TRF1 TRFH to at least WT levels ( Supplementary Fig. 2a ). The F142 residue of TRF1 stacks against the proline in the (F/I)XLXP motif of TERB1 (or TIN2; Fig. 1e ). Consistent with our crystal structure and previous results with TIN2 TBM (ref. 24) , the TRF1 F142A mutation abrogated TERB1 TBM binding (Supplementary Fig. 2b) .
We quantified the importance of individual TRF1-TERB1 interactions using a flow cytometry protein interaction assay (FCPIA) technique that has been previously described 25 . The TRFH domain of TRF1 was biotinylated on cysteines with biotin maleimide and immobilized on uniformly sized spherical streptavidin beads (Online Methods). The beads were incubated in the presence of increasing concentrations of GST-TERB1 TBM labeled with Alexa Fluor 488maleimide (which reacts with cysteine sulfhydryl groups, only present on GST) and the median fluorescence of the beads was analyzed by a flow cytometer. We determined a dissociation constant (K d ) of 75.1 ± 9 nM for the TRF1 TRFH -TERB1 TBM interaction ( Fig. 1i) . In contrast, TRF1 TRFH -TIN2 TBM binding was much stronger (K d = 5.3 ± 1.2 nM; Fig. 1i ), consistent with the more elaborate TRF1-TIN2 interface revealed by our structural analysis ( Fig. 1d) . We designed a competition experiment to quantitatively assess the TRF1-binding properties of TERB1 TBM mutants in the absence of labeling artifacts. For this experiment, Alexa Fluor 488-labeled TERB1 TBM was prebound to TRF1 TRFH -immobilized beads, and the fluorescence was measured as a function of titrated unlabeled TERB1 TBM WT or mutant peptides. As in direct binding assays, TIN2 TBM was a more efficient competitor than the TERB1 TBM WT protein ( Table 2, Fig. 1j and Supplementary Fig. 3a) . Additionally, TERB1 TBM I645E, L647E, T648E, P649E, and R652E were all severely impaired in their ability to displace WT TERB1 ( Table 2, Fig. 1j and Supplementary Fig. 3a ; statistics were derived from biological duplicates of means from technical duplicates). Indeed the TERB1 I645F mutation increased binding to TRF1 TRFH by ~3-fold compared to that of TERB1 WT ( Table 2 , Fig. 1j and Supplementary Fig. 3a) .
To validate the importance of the TRF1-TERB1 interface in a more biologically relevant context, we coexpressed and purified a minimal TERB1-TERB2 complex, TERB1 TRFB -TERB2 1-107 ( Supplementary  Fig. 3c-f ), based on domain definitions described for the corresponding complex in mice 22 . Competition analysis revealed that TERB1 TRFB -TERB2 1-107 WT showed a ~2-fold increase in affinity for TRF1 than that of TERB1 TBM , suggesting that although the TBM of TERB1 provides a large amount of the binding interface, structural determinants outside this region may also contribute to TRF1 binding ( Table 2 , Fig. 1k and Supplementary Fig. 3b ). As with mutant TERB1 TBM peptides ( Fig. 1j and Supplementary Fig. 3a ), TERB1 I645E, L647E, and P649E mutations in the context of TERB1 TRFB -TERB2 1-107 drastically reduced the binding affinity for TRF1 TRFH . Once again, the I645F displayed a moderate gain in binding affinity compared to that of the WT ( Table 2 , Fig. 1k and Supplementary Fig. 3b ). These results demonstrate the importance of the TBM of TERB1 for TRF1 binding.
Disruption of the TERB1-TRF1 interface compromises INM attachment of telomeres in prophase I of meiosis
We next tested the importance of the TRF1-TERB1 interface in vivo. We examined INM-telomere tethering in mouse Terb1 −/− spermatocytes, which have been shown to not undergo synapsis and to arrest in either leptotene or zygotene-like stages. Accordingly, in zygotene-like a r t i c l e s a r t i c l e s Terb1 −/− spermatocytes, the majority of TRF1-labeled telomeres remained detached from the nuclear membrane ( Fig. 2a-c) . This telomere attachment defect was rescued with exogenously provided TERB1 WT 21, 22 (Fig. 2a-c) . We attempted to rescue the Terb1 −/− phenotype with TERB1 TBM mutants. Expression of I645E, L647E, T648D, and the R651E R652E mouse TERB1 mutants showed a statistically significant defect in telomere attachment to the INM (Fig. 2b,c) . Like TERB1 WT, mouse TERB1 I645F efficiently rescued the telomere attachment defect of the Terb1 −/− spermatocytes (Fig. 2b,c) . Taking these results together, we conclude that even single mutations in the TRF1-TERB1 interface can considerably reduce both binding in vitro and telomere-INM tethering in vivo (summary in Supplementary  Table 1 ), thus highlighting the importance of this interface in proper progression through meiosis. Table 2 .
a r t i c l e s Further reinforcing the TERB1-TRF1 interaction interferes with cap exchange in prophase I of meiosis TRF1-TERB1 binding is critical for telomere attachment to the INM 21, 22 in early pachytene (histone H1 variant H1T negative), but dissociation of this complex is necessary for telomere-cap exchange later in pachytene 22 (H1T positive) ( Fig. 3a) . Upon cap exchange, shelterin proteins, including TRF1, are separated from the TERB1-TERB2-MAJIN complex, thus producing a more diffuse signal 22 ( Supplementary Fig. 4a ). Accordingly, the diameter of the TRF1 signals in late pachytene spermatocytes was greater than those in early pachytene spermatocytes ( Fig. 3a,d ; schematic in 3e).
We hypothesized that separation of the meiosis-specific proteins from shelterin during cap exchange is driven by the weakening of the TRF1-TERB1 interaction. Indeed, CDK-mediated phosphorylation of TERB1, which we show severely destabilizes the TRF1-TERB1 interface, occurs during cap exchange 22 . Not surprisingly, expression of loss-of-binding TERB1 (I645E, L647E, P649E, and R651E R652E) or TRF1 (F129A (equivalent of hTRF1 F142A)) mutants did not disrupt cap exchange in WT mouse spermatocytes (Fig. 3c,d and Supplementary Fig. 4b ). To further test our hypothesis, we designed gain-of-function mutants to further strengthen the TRF1-TERB1 interaction. Human TRF1 E106 interacts with T648 and is expected to electrostatically repel TERB1 PO 4 -T648 ( Fig. 1g) . We engineered the TRF1 E93K mutation (mouse TRF1 E93 is equivalent to hTRF1 E106) to create a positive charge suitable for interaction with TERB1 PO 4 -T648. GFP-TRF1 E93K expressed in late pachytene WT spermatocytes (H1T positive) appeared as compact rather than diffuse foci, whereas TRF1 E93A showed the normal, diffuse signal, like that of TRF1 WT (Fig. 3b,d) . Remarkably, the diameter of the GFP-TRF1 E93K signal in late pachytene was unchanged relative to that in early pachytene (Fig. 3b,d ). Because this experiment was performed in WT mouse spermatocytes, we also tracked the localization of endogenous TRF1 relative to that of GFP-TRF1 E93K. Indeed, endogenous TRF1 relocated to the periphery in late pachytene ( Supplementary Fig. 5a ), suggesting that barring interference by the E93K mutation, the cells are fully capable of undergoing normal cap exchange.
We also engineered mouse TERB1 I645F to further strengthen the TRF1-TERB1 interaction (Fig. 3c) . The late pachytene GFP-TERB1 signal that is normally compact and separated from the diffuse TRF1 signal (as in WT or I645E) spread out to the periphery in the presence of the I645F mutation ( Fig. 3c,e, and Supplementary Fig. 5b,c) . We infer that the reinforced binding allows endogenous TRF1 to drag with itself a subset of TERB1 I645F molecules to the periphery despite CDK-dependent phosphorylation of TERB1. These data suggest that reinforcing the interaction between TRF1 and TERB1 proteins interferes with cap exchange in vivo.
TERB1 and TIN2 bind TRF1 in a mutually exclusive manner
Because TRF1 protein is known to be a homodimer, it is unclear whether TERB1 and TIN2 can simultaneously bind TRF1 or whether the binding of these proteins to TRF1 is mutually exclusive. If TRF1 were able to simultaneously bind TIN2 and TERB1, it would imply that the same shelterin complex can perform both INM tethering and chromosome-end protection during meiosis. Our initial insights into this question came from the fluorescence-based competition assay previously described. We prebound streptavidin-beads-immobilized TRF1 TRFH with Alexa Fluor 488-labeled TERB1 TBM peptide. We then competed off this interaction using either the full-length human TIN2 protein or the TERB1 TRFB -TERB2 1-107 complex. We were surprised to observe that the height of the TERB1 TRFB -TERB2 1-107 competition curve was roughly half that of the TIN2 competition curve ( Fig. 4a and Supplementary Fig. 6a ). Given that each TRFH domain in the homodimer binds one TBM peptide (TERB1 or TIN2) ( Fig. 1c and ref. 24 ), these results suggest that two copies of full-length TIN2 can fully displace the two TBM peptides from TRF1, but only one TBM peptide is displaced by the TERB1 TRFB -TERB2 1-107 protein complex (schematic in Fig. 4a ).
To further test this idea, we engineered a fusion protein encompassing two TRF1 TRFH domains separated by a flexible glycine-serine linker. Using this system, we engineered three intramolecular TRF1 TRFH a r t i c l e s dimers: WT-WT (two TBM-binding sites), WT-F142A (one TBMbinding site), and F142A-F142A (no TBM-binding sites; Fig. 4b and Supplementary Fig. 6b,c) . Indeed, TIN2 showed the expected increase in binding stoichiometry when bound to WT-WT versus WT-F142A (compare TIN2 stoichiometry in lanes 7 and 8 in Fig. 4c ; replicate in Supplementary Fig. 6d and statistics in Supplementary Fig. 6e ). In contrast, TERB1-TERB2 did not show an increase in stoichiometry when binding WT-WT versus WT-F142A (compare TERB1 TRFB and TERB2 1-107 stoichiometries in lanes 3 and 4 in Fig. 4c ; replicate in Supplementary Fig. 6d and statistics in Supplementary Fig. 6e ). Thus, we conclude that TERB1-TERB2 can occupy only one TBM-binding site in a TRF1 dimer. The vacancy in the second binding site of TRF1 when bound by TERB1-TERB2 may potentially be occupied by TIN2 to recruit other shelterin proteins for chromosome-end protection. However, we failed to observe any TIN2 being pulled down on amylose beads containing MBP-TERB1 TRFB -TRF1 TRFH (lane 6, Fig. 4d ), suggesting that TRF1 is unable to simultaneously bind TIN2 and TERB1, at least in this experimental context ( Fig. 4e) .
Rap1 prevents binding of TERB1 to TRF2
It is known that TRF2 protein binds client proteins containing a YXLXP motif 24 . However, TRF1, but not TRF2, was identified as a binding partner of TERB1 (ref. 21) . We asked how the specificity for TRF1 versus TRF2 is achieved by TERB1. GST-TERB1 TBM pulls down TRF2 TRFH in vitro (Fig. 4f) . Direct and competition experiments of hTRF2 TRFH versus TRF1 TRFH revealed a roughly equal K d for both TRF protein domains binding TERB1 TBM peptide (TRF1 TRFH , 48 ± 8 nM; TRF2 TRFH , 42 ± 5 nM; Table 2 and Supplementary Fig. 7a,b) . However, competition analysis showed that TRF1 TRFH bound with greater affinity to the more physiologically relevant TERB1 TRFB -TERB2 1-107 complex than to the minimal TERB1 TBM , whereas the opposite trend was observed for TRF2 TRFH ( Table 2 ). The TERB1-TRF2 interaction was also less specific than the TRF1-TERB1 interaction, as TERB1 I645E and R652E mutations did not significantly affect TERB1-TRF2 binding ( Table 2 and Supplementary Fig. 7c,d) .
The highly abundant TIN2 and Rap1 proteins of shelterin are known to associate with TRF2, although Rap1 is also involved in forming a higher-order complex with TRF2 (four subunits each of TRF2 and Rap1) 24, 26, 27 . Accordingly, we asked whether the binding of TIN2 or Rap1 affects the TERB1-TRF2 interaction. Binding of TERB1 to TRF2 was severely hampered in the presence of the Rap1 protein ( Fig. 4g) . Furthermore, ternary pulldown experiments demonstrated that although MBP-TERB1 TRFB binds TRF2, it fails to do so in the presence of Rap1 (compare lanes 5 and 6, Supplementary Fig. 7e) . A similar pulldown experiment showed that TIN2 does not interfere with the TRF2-TERB1 interaction (Supplementary Fig. 7f ). These results suggest that the association of TRF2 and Rap1 at telomeres possibly prevents a noncognate TERB1-TRF2 interaction during meiosis.
DISCUSSION
The unique role played by telomeres in meiotic cells raises several mechanistic questions with broad implications in both chromosome-end Terb1 Quantitation shows that GFP-TERB1 I645F distributes to the wider area compared to WT protein presumably because of its persistent interaction with TRF1, which relocates to the surrounding area after cap exchange.
a r t i c l e s TERB1 does, (ii) the TBM of TERB1 provides a large fraction of the binding interface with TRF1, and (iii) mutations in the L647, P649 and R652 residues in the TERB1 TBM drastically reduce binding to TRF1 and impair INM attachment of telomeres in Terb1 −/− spermatocytes expressing TERB1 TBM mutant proteins. However, we also note that none of the TERB1 mutants reduced telomere-INM tethering to the levels seen in Terb1 −/− spermatocytes. This is probably because the attachment of TERB1-TERB2-MAJIN to telomeres may involve binding of TRF1 to regions of TERB1 outside its TBM, as well as the binding of MAJIN 22 and TERB1 (ref. 21) to telomeric DNA. Second, how is the telomere-INM assembly rearranged during cap exchange? We wondered whether the variations in TERB1 TBM relative to TIN2 (phenylalanine→isoleucine in (F/I)XLXP and phosphorylation of TERB1 T648) are adaptations to attenuate the TERB1-TRF1 interaction for achieving cap exchange. Indeed, the phosphomimetic mutation of T648 abrogated binding of TERB1 to TRF1 in vitro and reduced telomere tethering to the INM ~15-fold relative to that of WT TERB1 in vivo. This finding is fully consistent with a highly unfavorable electrostatic repulsion between TERB1 PO 4 -T648 and human TRF1 E106. We predicted that further reinforcing the TERB1-TRF1 interaction would compromise proper cap exchange. Indeed, expression of gain-of-binding mutants of mouse TRF1 E93K and mouse TERB1 I645F interfered with normal cap exchange. We conclude that the dynamic nature of the TERB1-TRF1 interaction in biology mandates an interface that is robust enough to initially anchor telomeres to the INM, but also malleable enough to allow dissociation as meiosis progresses. Furthermore, our observation that one but not both binding sites in a TRF1 dimer are available for binding TERB1 suggests yet another adaptation to facilitate TRF1-TERB1 dissociation during cap exchange.
Third, how is the meiosis-specific function of telomeres compatible with chromosome-end protection in early and late pachytene? The a r t i c l e s interaction between TRF1 and TIN2 is essential for chromosome-end protection by shelterin, as disruption of this interaction results in both ATR-mediated and ATM-mediated DNA-damage response at telomeres 28, 29 . Our binding experiments suggest that the end-protection-specific and meiosis-specific functions of TRF1 are bestowed on separate pools of TRF1 protein (Fig. 4e) . Although TRF1 bound to TIN2 would perform normal end protection in early pachytene, this complex would not bind TERB1. Conversely, TRF1 bound to TERB1 would tether telomeres to the INM, but this TRF1 pool would be unable to bind TIN2 to assemble the rest of shelterin.
In late pachytene, one model is that TERB1-TERB2-MAJIN takes over telomeric DNA by releasing the shelterin complex into a surrounding ring structure (cap exchange). In this window of the cell cycle, TERB1-TERB2-MAJIN may completely replace shelterin for performing end protection. However, it is intriguing that shelterin, although not localized at telomeric DNA, is still in its immediate vicinity after cap exchange 22 . One explanation for how shelterin remains close to telomeric DNA without binding either DNA or TERB1 is that it phase separates en bloc, forming an oil-dropletlike structure around it. Such condensates have been observed in various other biological contexts, including DNA-damage response, RNA storage and stability, and ribosome biogenesis 30 . Another possibility is that TERB1-TERB2-MAJIN displaces shelterin from the extreme chromosome ends to internal telomeric or subtelomeric regions (closer to centromeres) in late pachytene. Under such a setup, TERB1-TERB2-MAJIN and shelterin could share the burden of chromosome-end protection. Finally, it is also possible that the spatial separation of complexes observed in cap exchange denote separation of TERB1-TERB2-MAJIN and shelterin on different telomeric structures (for example, t-loops) or chromatin states in late pachytene (rather than different loci on chromosomes). Although shelterin will continue to protect chromosome ends as usual, TERB1-TERB2-MAJIN, as part of the altered telomeric structure and/or chromatin state, might allow proper anchoring of the ends of chromosomes to the INM.
Fourth, how is specificity for TRF1 versus TRF2 established for TERB1? Our data provide multiple lines of evidence to suggest that the cognate binding partner of TERB1 is TRF1, not TRF2. (i) TRF1 but not TRF2 prefers binding to TERB1 TRFB -TERB2 1-107 over the TERB1 TBM peptide, suggesting that TRF1 has adapted to bind TERB1 and TRF2 has not. (ii) The TRF2-TERB1 interaction is less specific compared to the TRF1-TERB1 interaction, insofar as TRF2 binding is insensitive to certain mutations in the TERB1 TBM. (iii) Binding of TERB1 to TRF2 is abrogated in the presence of Rap1, an abundant human shelterin protein 31 that binds strongly to TRF2 (ref. 32) and is present along with the rest of shelterin at meiotic telomeres 22 .
In summary, our studies unravel a structural interface that is critical for tethering telomeres to the INM, validate its importance in vivo, define the rules guiding not only its formation but also its cell-cycledependent dissociation in meiotic cells, and provide a rationale for how this interface is able to sustain chromosome-end protection and simultaneously avoid noncognate interactions.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS
Primers, cDNA, and plasmid constructs. All primers were purchased from Integrated DNA Technologies (IDT). The pSmt3 vector used to generate His-Smt3 fusions in Escherichia coli 33 was obtained from C. D. Lima upon signing a material transfer agreement with Cornell University, New York. Coexpression of recombinant proteins in E. coli was performed using the pET-Duet vector (Novagen). For expression in baculovirus-infected insect cells, the expression constructs were cloned into the pFastbac vector (Life Technologies) encoding an N-terminal His-Sumostar tag (Lifesensors). pSmt3-TERB1-523-656 (for TERB1 TRFB protein) and pSmt3-TERB1-643-656 (for TERB1 TBM peptide) were generated by PCR amplifying the sequences from hTERB1 cDNA (gene block; IDT). PCR inserts post-restriction digestion were ligated into pSmt3 vector using BamHI (New England Biolabs, NEB) and XhoI sites (NEB). A hTERB2 cDNA clone was obtained from GE Healthcare/Dharmacon (clone: MHS6278-202809054) and the sequence encoding residues 1-107 was amplified by PCR, cloned into the pSmt3 vector as described for TERB1. For coexpression experiments, hTERB1 TRFB and hTERB2 1-107 sequences were cloned into the pET-Duet vector (Novagen) with TERB1 harboring a 10×-His-Smt3 tag and TERB2 expressed without a tag. hTRF1 TRFH , hTRF2 TRFH , and full-length hTRF2 were amplified from cDNA and cloned into the pSmt3 vector. Full-length hTIN2-and hRap1-coding regions were amplified from cDNA and cloned into the pSumostar-Fastbac vector backbone for expression in High Five insect cells (Life Technologies). For GST-tagged and His-Smt3-MBP-tagged constructs, BamHI and XhoI double-digested inserts were ligated into the pGEX-6P-2 vector (GE Life Sciences) and the pSmt3-MBP vector (derived by cloning the MBP cDNA into pSmt3), respectively. Intramolecular hTRF1 TRFH homodimeric constructs were cloned in the pSmt3 vector using two tandem hTRF1 TRFH cDNA sequences separated in frame by DNA sequence coding for a five amino acid glycine-serine linker.
Site-directed mutagenesis of plasmids. Mutations in both TERB1 and TRF1 expression plasmids were introduced using the QuikChange Site-Directed Mutagenesis kit (Agilent Technologies) and complementary mutagenic primers (IDT). Sanger sequencing was used to confirm the presence of the intended mutation and absence of unwanted sequence changes introduced during the cloning process.
Protein expression and purification. WT and mutant constructs of His-Smt3-TRF1 TRFH , His-Smt3-TRF2 TRFH , GST-TRF1 TRFH , GST-TRF2 TRFH , GST-TERB1 TBM , and TRFH intramolecular dimers were expressed in BL21(DE3) cells, and His-Smt3-TERB1 TBM , His-Smt3-TERB1 TRFB -TERB2 1-107 , and His-MBP-Smt3-TERB1 TRFB were expressed in Rosetta(DE3) codon supplemented cells. Expression of recombinant proteins in E. coli was induced with isopropyl βd-thiogalactopyranoside. Nickel-agarose affinity chromatography was used as the first step of purification of His-Smt3-tagged proteins. His-Smt3-TERB1 TBM WT and mutant proteins used for pulldowns and binding studies were not subjected to removal of the Smt3 tag. All other Smt3 fusions were cleaved with Ulp1 protease to remove the His-Smt3 tag and purified further using size-exclusion chromatography (Superdex 75 for proteins and complexes < 50 kDa and Superdex 200 for proteins and complexes > 50 kDa; GE Healthcare). Full-length human TIN2 and Rap1 proteins were expressed in baculovirus-infected High Five insect cells (Life Technologies) as His-Sumostar fusion proteins using the manufacturer's protocol. Subsequent purification was performed as described for Smt3-tagged proteins with the exception that Sumostar protease (Lifesensors) was used to cleave the His-Sumostar tag. Anion-exchange (HiTrap Q; GE Healthcare) was performed as the final polishing step of purification of Rap1 and TIN2. GST-tagged proteins were purified using Glutathione Sepharose 4B beads (GE Healthcare), following the manufacturer's instructions. TERB1 643-656 used for crystallography, after removal of the His-Smt3 tag, was purified further via size-exclusion chromatography (Superdex 75; GE Healthcare) in 100 mM ammonium bicarbonate buffer, lyophilized, and resuspended in water before being subjected to cocrystallization with TRF1 TRFH .
Pulldown assays. For GST-glutathione beads pulldown experiments, 30 µl of a 1:1 slurry of glutathione Sepharose 4B beads (GE Healthcare) prewashed three times with binding buffer (25 mM Tris-Cl, pH 8.0, 150 mM NaCl, and 2 mM 2-mercaptoethanol) was incubated with 20 µg of GST-tagged bait protein for 1 h at 4 °C. 20 µg of prey protein was then added and incubation continued for 1 h at 4 °C.
The beads were then washed three times with binding buffer and heated at 95 °C for 10 min in denaturing SDS gel-loading dye. The proteins were resolved on a 15% SDS-PAGE gel and visualized with Coomassie blue stain. MBP-Amylose beads pulldown experiments were performed similarly, but with Amylose Resin High Flow (NEB) and MBP-tagged bait proteins. Quantitation of Coomassiestained SDS-PAGE pulldown data was performed using the ImageJ software. In all cases, background-corrected band intensities were divided by the molecular weight of the species and then normalized against the molecular weight-normalized intensity of the bait protein in that lane.
Flow-cytometry based assay for quantifying protein-protein interactions.
Direct binding experiments. Proteins were typically labeled as described in Blazer et al. 25 . Specifically, we reacted a 2-5-fold excess of label over protein concentration for 30 min at room temperature. Unreacted label was removed with a Micro Bio-spin 6 spin column (Bio-Rad), and protein concentration was measured by the Protein Assay Reagent (Bio-Rad). The bait protein was biotinylated using biotin maleimide (Sigma; B1267) and immobilized on uniformly sized streptavidin beads (Spherotech; SVP-20-5). 6 µl of beads was used for an entire 96-well plate. The prey protein was fluorophore labeled at cysteine residues (Alexa Fluor488-C5-maleimide, Life Technologies) and varying concentrations of prey proteins were mixed with the bait protein on beads in a buffer containing 20 mM Tris-Cl, pH 8.0, 100 mM NaCl, 2 mM DTT, 1% BSA, and 0.1% lubrol. Upon equilibration on ice for 30 min, samples were loaded on an Accuri C6 flow cytometer (BD Biosciences) using a Hypercyt autosampler (IntelliCyt). In every experiment, the median fluorescence intensity from each titration point was scored from approximately 500-1,500 beads using the flow cytometer. Median fluorescence intensity on the beads was calculated using the Hypercyt software for a technical duplicate from the same plate, and the obtained mean values of the duplicate measurements were fitted to a single site binding model and K d values calculated using Prism 7.0 (GraphPad) after subtracting background data from the same experiment performed without any bait protein bound to beads. We treated each site in the TRF1 (or TRF2) homodimer as an independent site in our analysis, because we did not observe binding profiles suggestive of cooperativity. We note that the direct binding technique used here potentially underestimates the binding affinity (i.e., overestimates K d ), because labeling at or close to the interface will likely reduce affinity. Direct binding experiments were performed either two or three times.
Competition experiments. The two interacting proteins were labeled with biotin and fluorophore, respectively, as in direct binding studies, and held at a constant concentration throughout the experiment. Competition analysis was performed using 30 nM Alexa Fluor 488-labeled GST-TERB1. The unlabeled competitor protein was titrated into this mixture, and fluorescence intensity measurements were conducted as previously described except that incubation of binding mixtures before flow cytometry was performed for 1 h to ensure equilibration. Median fluorescence values were fitted to a one-site competition curve and IC 50 values calculated in Prism 7.0 (GraphPad). Competition experiments were performed either two or three times.
Structure determination of the TRF1 TRFH -TERB1 TBM . TRF1 TRFH and TERB1 TBM were mixed in a 1:5 molar ratio, and crystal screens were set up using 0.3 µl protein solution and 0.3 µl reservoir solution in a sitting-drop format. Diffracting crystals were obtained in 0.1 M Tris-Cl, pH 8.5, and 30% PEG 300. Crystals were cryoprotected in the crystallization solution plus 10% PEG 400 and harvested in liquid nitrogen. Diffraction data were collected at the LS-CAT beamline 21 ID-F at the Argonne National Laboratory at 0.97872-nm wavelength and 100 K temperature, indexed and processed using Mosflm (CCP4i 34 ), and scaled using Aimless (CCP4i). Molecular replacement was performed using Molrep (CCP4i) with the structure of the TRF1 TRFH domain (PDB 3BQO) serving as a search model. Preliminary refinement of the molecular replacement solution was performed using REFMAC (CCP4i), and the model was built in Coot 35 . The final rounds of refinement were performed using Phenix 36 . The final structural model exhibited excellent geometry and contained no residues in the disallowed regions of the Ramachandran plot. Figures depicting structures were prepared in PyMOL (http://www.pymol.org/).
Animals.
For telomere-attachment analysis, Terb1-knockout mice (Terb1 tm2a(KOMP)Mbp ) on a C57BL/6J background 21 were used. For telomere cap exchange analysis, C57BL/6J mice were purchased from Japan SLC, Inc. (Shizuoka, Japan). Animal experiments complied with ethical regulations and were approved by the Institutional Animal Care and Use Committee (approval #2809). No statistical method was used to estimate sample size.
Antibodies for in vivo analysis. The following antibodies were used in the mouse studies: mouse antibody against TRF1 (1:2,000 dilution, in-house) 21 , chicken antibody against GFP (1:500 dilution, Abcam, ab13970), guinea pig antibody against H1t (1:500 dilution, courtesy of the Handel lab) 37 , rat antibody against SYCP3 (1:200 dilution, in-house) 21 .
Exogenous expression of TRF1 and TERB1 in mouse testis. Plasmid DNA was injected into live-mouse testes based on a previously reported method with some modifications 38 . Briefly, mice at 20 d postpartum for WT mice and 30 d postpartum for Terb1 −/− mice were anesthetized. 50 µg of plasmid DNA (10 µl of 5 µg/µl DNA solution) was injected into the rete testis using a glass capillary under a stereomicroscope. After 60 min, electric pulses were applied four times at 50 V for 50 ms at 950-ms intervals, and the same electric pulses were applied again in the reverse direction. The testes were then placed in the abdominal cavity. After 24 h or 72 h of electroporation for WT or Terb1 −/− mice, respectively, the mice were euthanized. The testes were extracted and used for cell preparations as described below.
Immunostaining of mouse spermatocytes. We followed a procedure described previously with some modifications 22 . Briefly, seminiferous tubules were extracted from the testes and minced using forceps. Germ cells were collected by pipetting for 1-2 min, washed three times with PBS, and the collected cells were resuspended in hypotonic buffer (30 mM Tris-Cl, pH 7.5, 17 mM Tris-sodium citrate, 5 mM EDTA, and 50 mM sucrose) for 5 min at RT. After centrifuging at 500g for 5 min, the cells were resuspended in fixation buffer (1.5% PFA, 0.1% Triton X-100, and 100 mM sucrose in PBS) and placed on glass slides for 6 h or overnight at RT. After fixation, the cells were air dried and used for immunostaining. The cells were permeabilized by incubating the slides in 0.1% Triton X-100 in PBS for 15 min at RT and washing twice with PBS. For immunostaining, the slides were incubated with 5% BSA in PBS for 30 min at RT. First, the primary antibodies listed above were applied and the slides were incubated overnight at RT, after which the slides were incubated with secondary antibodies conjugated with Alexa Fluor 488, 568 or 647 (Life Technologies) (1:500 dilution) for 2 h at RT. The slides were washed with PBS and mounted using VECTASHIELD mounting medium with DAPI (VECTOR Laboratories).
Microscopy of mouse spermatocytes. Images were obtained on an IX-70 microscope (Olympus) equipped with a Delta Vision core system (GE Healthcare) and a CoolSNAP HQ CCD camera (Roper Scientific). A total of 100-140 Z sections were acquired in 0.1-µm steps using Olympus 100× 1.35NA UPlanApo objectives. The images were deconvolved using softWoRx version 5.5.5 acquisition software (GE Healthcare), and stacked images were analyzed for measurements. The width and area of telomere signals were measured using Fiji software 39 . For visualization purposes, magnified pictures of telomeres were cropped from a stacked picture of selected sections containing the target telomere using Fiji software 39 , and the contrast of the image was enhanced using Photoshop (Adobe). to define statistical significance and was indeed sufficient to discern statistically significant differences in the current study too.
Statistics for in vivo
Data exclusions
Describe any data exclusions. No data were excluded. As is common practice, for the calculation of R-free of the crystal structure, 5% of the diffraction data was excluded (randomly selected by data reduction program) from refinement to serve as a model-unbiased statistical criterion for structure refinement.
Replication
Describe whether the experimental findings were reliably reproduced.
All replicates were successful for experiments. The crystal structure is reported for only one crystal although datasets collected for several other crystals grown under the same or different conditions furnished the same space group and unit cell dimensions. It was not deemed necessary to solve the structures from the other crystals that diffracted to lower resolution. The structure was determined from the crystal that diffracted to the highest resolution and had the most superior scaling statistics.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
In the mouse studies, the animals were chosen randomly.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was unnecessary for quantitative in vitro fluorescence-based experiments because they were all analyzed using digital data (i.e., numbers) obtained from the fluorescence detector and analyzed directly by Prism software using a singlebinding site equation. Blinding was not performed in the mouse experiments. For Figure 2 quantitation, the peripheral spots are easily distinguished from internal spots. For Figure 3 quantitation, the diameter/width of the signal was measured using imaging software.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used. n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
Nature
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
CCP4 and Phenix suites were used to analyze crystallography data and solve the crystal structure. The images depicting the entire structure or its parts were prepared using Pymol.
ImageJ was used to quantify band intensities of coomassie-stained SDS-PAGE gels.
Intensities were normalized using MS Excel.
Median fluorescence intensity for the quantitative binding experiments was calculated using the Hypercyt software and the obtained values were fitted to a single site binding model and dissociation constant (Kd) values calculated using Prism 7.0 (Graphpad) after subtracting background data from the same experiment performed without any bait protein bound to beads.
For in vivo microscopy experiments in mouse spermatocytes, the acquired images were processed with Photoshop (Adobe) and Fiji software (ref 40). For visualization purposes, magnified pictures of telomeres were cropped from a stacked picture of selected sections containing the target telomere using Fiji software (ref 40), and the contrast of the image was enhanced using Photoshop.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
Reagents generated from this study are available upon request to the corresponding author. Reagents (such as antibodies) obtained from other labs or commercially may be requested/purchased directly from those sources.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
The following antibodies were used in the mouse studies: mouse antibody against TRF1 (1:2000 dilution; in-house; see ref 21) , chicken antibody against GFP (1:500 dilution, Abcam, ab13970), guinea pig antibody against H1t (1:500 dilution, courtesy Handel lab; see ref 38) , rat antibody against SYCP3 (1:200 dilution; inhouse; see ref 21) . All antibodies have been validated previously. For in-house antibodies, please refer to cited references. For commercial antibody please refer to vendor website.
